Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)
Shots:
- Evotec and GARDP enter into an agreement to develop novel therapies for growing threat of antimicrobial resistance (AMR)
- The focus of the collaboration is to combine GARDP’s clinical expertise with Evotec’s drug discovery platform to develop antibiotics for AMR and establish antibiotic discovery- development platform with portfolio of antibiotic assets
- Evotec’s anti-infective platform enabling discovery and development of vaccines to treat- prevent serious life-threatening infections arising from Gram-positive and Gram-negative bacteria including MDR organism with a collection of strains producing in-vitro and in-vivo therapies
Ref: Evotec | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com